Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)
52.1Fair
ValueMarkers Composite Index
Top 48%#23,678 of 45,192
Overvalued
41% above intrinsic value ($284)
UndervaluedFair ValueOvervalued
Piotroski
9/9
StrongBeneish
-2.65
Low RiskAltman
8.18
SafeDCF Value
$284
OvervaluedROIC
13.9%
AdequateP/E
17.3
FairUpdated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Deep Dive Analysis
DCF Analysis
Intrinsic value estimate, margin of safety, and key valuation metrics.
DCF: $284.40MOS: -41%Graham: $26.57
Piotroski F-Score
9-point financial strength test across profitability, leverage, and efficiency.
F-Score: 9/9
Quality Triple Check
Piotroski F-Score + Altman Z-Score + Beneish M-Score combined assessment.
F: 9/9Z: 8.2M: -2.6
Valuation Analysis
Complete multiples breakdown - P/E, P/B, EV/EBITDA, yield metrics, and intrinsic value.
P/E: 17.3P/B: 6.6EV/EBITDA: 10.9